Literature DB >> 6421941

Serum sensitivity of Neisseria gonorrhoeae: the role of lipopolysaccharide.

W M Shafer, K Joiner, L F Guymon, M S Cohen, P F Sparling.   

Abstract

A lipopolysaccharide (LPS) mutant (FA5100) of a serum-resistant strain of Neisseria gonorrhoeae (FA19) was found to be highly sensitive to the bactericidal activity of normal human serum (NHS). Both strain FA5100 and an unrelated serum-sensitive clinical isolate (F62) were killed by NHS via the classical complement pathway since killing required C2 and Ca++. However, the fact that only strain FA5100 was sensitive to human hypogammaglobulinemic and cord serum suggested that this strain might activate the classical complement pathway in the absence of antibody. Anticomplementary concentrations of LPS from strain FA5100 inhibited the bactericidal activity of NHS against either strain FA5100 or strain F62. However, concentrations of LPS from strain FA5100 that exhibited marginal anticomplementary behavior also inhibited the killing of strain F62 by NHS. The ability of LPS from strain FA5100 to inhibit the bactericidal activity of NHS against strain FA5100 and to activate complement was reduced by treatment with mild alkali. However, alkali-treated LPS from strain FA5100 still inhibited the bactericidal activity of NHS against strain F62.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421941     DOI: 10.1093/infdis/149.2.175

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

1.  Rhizobium leguminosarum CFN42 genetic regions encoding lipopolysaccharide structures essential for complete nodule development on bean plants.

Authors:  J R Cava; P M Elias; D A Turowski; K D Noel
Journal:  J Bacteriol       Date:  1989-01       Impact factor: 3.490

2.  Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing.

Authors:  S Merino; S Camprubí; S Albertí; V J Benedí; J M Tomás
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Differential regulation of ponA and pilMNOPQ expression by the MtrR transcriptional regulatory protein in Neisseria gonorrhoeae.

Authors:  Jason P Folster; Vijaya Dhulipala; Robert A Nicholas; William M Shafer
Journal:  J Bacteriol       Date:  2007-05-04       Impact factor: 3.490

4.  Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing.

Authors:  S Merino; X Rubires; A Aguilar; S Albertí; S Hernandez-Allés; V J Benedí; J M Tomas
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

5.  Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein.

Authors:  Sunita Gulati; Sarika Agarwal; Shreekant Vasudhev; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

6.  Polyamines can increase resistance of Neisseria gonorrhoeae to mediators of the innate human host defense.

Authors:  Maira Goytia; William M Shafer
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

Review 7.  Introduction of cloned genes into Neisseria gonorrhoeae.

Authors:  D C Stein
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

8.  Interaction of Neisseria gonorrhoeae with classical complement components, C1-inhibitor, and a monoclonal antibody directed against the Neisserial H.8 antigen.

Authors:  J E Schweinle; P J Hitchcock; A J Tenner; C H Hammer; M M Frank; K A Joiner
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

9.  Defining targets for complement components C4b and C3b on the pathogenic neisseriae.

Authors:  Lisa A Lewis; Sanjay Ram; Alpana Prasad; Sunita Gulati; Silke Getzlaff; Anna M Blom; Ulrich Vogel; Peter A Rice
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

10.  Ability of gonococcal and meningococcal lipooligosaccharides to clot Limulus amebocyte lysate.

Authors:  R I Roth; R Yamasaki; R E Mandrell; J M Griffiss
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.